<p>"The company has received 180 days marketing exclusivity," Sun Pharma said in a statement, adding that approval is for multiple doses of strengths of 37.5 mg (base), 75 mg (base) and 150 mg (base).<br /><br />These tablets are equivalent to Osmotica's Venlafaxine hydrochloride extended release tablets. Osmotica, a global pharmaceutical company specialises in drug delivery technologies and neuro based therapies.<br /><br />Extended release tablets use a mechanism by which the tablets dissolve slowly and release a drug over time. They are taken less frequently and keep steadier levels of drug in the blood stream.<br /><br />The shares of the company were trading at Rs 1,795.20 at the Bombay Stock Exchange in morning trade, up by 1.65 per cent over the previous close.</p>
<p>"The company has received 180 days marketing exclusivity," Sun Pharma said in a statement, adding that approval is for multiple doses of strengths of 37.5 mg (base), 75 mg (base) and 150 mg (base).<br /><br />These tablets are equivalent to Osmotica's Venlafaxine hydrochloride extended release tablets. Osmotica, a global pharmaceutical company specialises in drug delivery technologies and neuro based therapies.<br /><br />Extended release tablets use a mechanism by which the tablets dissolve slowly and release a drug over time. They are taken less frequently and keep steadier levels of drug in the blood stream.<br /><br />The shares of the company were trading at Rs 1,795.20 at the Bombay Stock Exchange in morning trade, up by 1.65 per cent over the previous close.</p>